Most researchers trying to source CJC-1295 in Mapo immediately realize that local retail options are essentially nonexistent. What this means for Mapo researchers is that geography is secondary to your ability to evaluate vendor quality — and those verification methods are accessible to anyone. A legitimate CJC-1295 supplier's COA must contain HPLC purity, mass spectrometry confirmation of molecular identity, bacterial endotoxin testing, and a residual solvents panel — all traceable to your specific batch. The sections below cover what Mapo researchers need to know about sourcing, verifying, and handling CJC-1295 for research purposes.
What Studies Say About CJC-1295
CJC-1295 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Mapo studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
How to Evaluate CJC-1295 Vendors
Evaluating CJC-1295 vendors starts with the COA: locate the batch-specific certificate before purchasing, not after. A COA for CJC-1295 should include: HPLC purity percentage with the full chromatographic trace, mass spectrometry data verifying the correct molecular weight, endotoxin test results, and a residual solvent panel — all specific to the lot you receive. For Mapo researchers evaluating new suppliers: a modest first purchase to test the product before committing to research quantities is standard practice in the community. Keep lyophilised CJC-1295 at −20°C until ready to use; reconstitute only the amount needed for the near-term protocol and keep the remainder frozen.
Order CJC-1295 — ships to Mapo
COA-verified · International tracking · Research grade
All use of CJC-1295 in Mapo or anywhere is research use only — this compound is not approved for human therapeutic use, and all handling should adhere to research compound handling standards. Lyophilised CJC-1295 should be stored frozen (−20°C) immediately upon receipt; do not freeze and thaw reconstituted CJC-1295 multiple times by aliquoting into single-use portions. The primary quality-related safety risk in CJC-1295 research is bacterial endotoxin from low-quality material — a confirmed endotoxin test result in the lot-matched COA is the key safeguard. Researchers using CJC-1295 alongside other research compounds should review the available literature for documented interactions before running stacked compound experiments.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
